 Jonathan Kurche
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 11 | 2025 | 657 | 2.280 |
Why?
| | Mucin-5B | 7 | 2025 | 224 | 2.060 |
Why?
| | Interleukin-6 | 2 | 2022 | 778 | 0.720 |
Why?
| | Orthomyxoviridae Infections | 1 | 2019 | 67 | 0.600 |
Why?
| | Cysts | 1 | 2019 | 113 | 0.590 |
Why?
| | Bleomycin | 4 | 2023 | 248 | 0.520 |
Why?
| | Phenotype | 1 | 2024 | 3196 | 0.490 |
Why?
| | OX40 Ligand | 2 | 2011 | 10 | 0.440 |
Why?
| | Interferon Type I | 2 | 2011 | 140 | 0.430 |
Why?
| | Dendritic Cells | 3 | 2011 | 483 | 0.430 |
Why?
| | Receptor, Interferon alpha-beta | 2 | 2011 | 34 | 0.390 |
Why?
| | Membrane Glycoproteins | 2 | 2011 | 500 | 0.380 |
Why?
| | Tumor Necrosis Factors | 1 | 2011 | 11 | 0.380 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1431 | 0.370 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1040 | 0.340 |
Why?
| | CD27 Ligand | 1 | 2010 | 9 | 0.340 |
Why?
| | Promoter Regions, Genetic | 2 | 2025 | 1250 | 0.310 |
Why?
| | T-Lymphocyte Subsets | 1 | 2011 | 417 | 0.310 |
Why?
| | Pulmonary Fibrosis | 2 | 2022 | 402 | 0.280 |
Why?
| | Lymphocyte Activation | 1 | 2011 | 1142 | 0.280 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2011 | 1091 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2011 | 900 | 0.270 |
Why?
| | Respiratory Mucosa | 4 | 2025 | 321 | 0.270 |
Why?
| | Lung Diseases, Interstitial | 2 | 2021 | 638 | 0.220 |
Why?
| | Mice | 9 | 2023 | 17787 | 0.210 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2023 | 29 | 0.210 |
Why?
| | Peptide Hydrolases | 1 | 2022 | 111 | 0.180 |
Why?
| | Animals | 12 | 2025 | 36940 | 0.170 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2167 | 0.170 |
Why?
| | Cell Communication | 1 | 2022 | 315 | 0.170 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2021 | 83 | 0.170 |
Why?
| | Ligands | 1 | 2022 | 664 | 0.170 |
Why?
| | Lung | 5 | 2025 | 4060 | 0.160 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2020 | 97 | 0.160 |
Why?
| | Keratin-15 | 1 | 2019 | 16 | 0.160 |
Why?
| | Colloids | 1 | 2019 | 60 | 0.160 |
Why?
| | Pulmonary Alveoli | 2 | 2025 | 405 | 0.150 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 83 | 0.150 |
Why?
| | Aged | 6 | 2025 | 23961 | 0.150 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 148 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 786 | 0.140 |
Why?
| | Mice, Knockout | 4 | 2011 | 3015 | 0.130 |
Why?
| | Bronchioles | 1 | 2016 | 23 | 0.130 |
Why?
| | Mucociliary Clearance | 1 | 2016 | 45 | 0.130 |
Why?
| | Cholestyramine Resin | 1 | 2015 | 7 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2426 | 0.120 |
Why?
| | RNA | 1 | 2022 | 921 | 0.120 |
Why?
| | Hemothorax | 1 | 2015 | 11 | 0.120 |
Why?
| | Isoxazoles | 1 | 2015 | 54 | 0.120 |
Why?
| | Pericardial Effusion | 1 | 2015 | 19 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2057 | 0.120 |
Why?
| | Cells, Cultured | 3 | 2011 | 4193 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2607 | 0.110 |
Why?
| | Prosthesis-Related Infections | 1 | 2015 | 95 | 0.110 |
Why?
| | Humans | 15 | 2025 | 137585 | 0.110 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 224 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1774 | 0.100 |
Why?
| | Shock, Septic | 1 | 2015 | 219 | 0.100 |
Why?
| | Mice, Inbred C57BL | 4 | 2011 | 5757 | 0.100 |
Why?
| | Antirheumatic Agents | 1 | 2015 | 293 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.100 |
Why?
| | Radiation Chimera | 1 | 2011 | 29 | 0.090 |
Why?
| | Mice, 129 Strain | 1 | 2011 | 88 | 0.090 |
Why?
| | Cross-Priming | 1 | 2011 | 15 | 0.090 |
Why?
| | Toll-Like Receptor 7 | 1 | 2011 | 39 | 0.090 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2010 | 28 | 0.080 |
Why?
| | Vaccinia virus | 1 | 2010 | 43 | 0.080 |
Why?
| | Female | 7 | 2025 | 73304 | 0.080 |
Why?
| | Antigen Presentation | 1 | 2011 | 218 | 0.080 |
Why?
| | Male | 7 | 2025 | 67762 | 0.080 |
Why?
| | CD40 Antigens | 1 | 2010 | 89 | 0.080 |
Why?
| | Toll-Like Receptors | 1 | 2010 | 185 | 0.080 |
Why?
| | Signal Transduction | 3 | 2011 | 5079 | 0.080 |
Why?
| | Listeria monocytogenes | 1 | 2010 | 126 | 0.080 |
Why?
| | Middle Aged | 3 | 2025 | 33479 | 0.070 |
Why?
| | Immunization | 1 | 2010 | 411 | 0.070 |
Why?
| | Myocardial Infarction | 1 | 2015 | 1046 | 0.070 |
Why?
| | B7-2 Antigen | 1 | 2007 | 27 | 0.070 |
Why?
| | Vaccines | 1 | 2012 | 406 | 0.070 |
Why?
| | B7-1 Antigen | 1 | 2007 | 58 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 81 | 0.070 |
Why?
| | Stroke | 1 | 2015 | 1120 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1178 | 0.060 |
Why?
| | Laser Capture Microdissection | 1 | 2025 | 33 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2007 | 363 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2007 | 385 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1996 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2B | 1 | 2023 | 6 | 0.050 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2023 | 110 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2021 | 24 | 0.050 |
Why?
| | Epithelium | 1 | 2022 | 313 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 113 | 0.040 |
Why?
| | A549 Cells | 1 | 2021 | 66 | 0.040 |
Why?
| | Gain of Function Mutation | 1 | 2021 | 36 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 552 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2021 | 56 | 0.040 |
Why?
| | Heart Transplantation | 1 | 2007 | 754 | 0.040 |
Why?
| | Proteome | 1 | 2025 | 472 | 0.040 |
Why?
| | Fibroblasts | 1 | 2025 | 996 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 190 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 206 | 0.040 |
Why?
| | Lung Injury | 1 | 2021 | 219 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 1111 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.040 |
Why?
| | Models, Genetic | 1 | 2021 | 600 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2021 | 324 | 0.030 |
Why?
| | Binding Sites | 1 | 2021 | 1303 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 971 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 519 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2022 | 1096 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 660 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2847 | 0.030 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 92 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2189 | 0.030 |
Why?
| | Vaccines, Subunit | 1 | 2012 | 49 | 0.020 |
Why?
| | Immunity, Humoral | 1 | 2012 | 116 | 0.020 |
Why?
| | Receptors, Interleukin-12 | 1 | 2011 | 7 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 268 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2011 | 99 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7635 | 0.020 |
Why?
| | Transplantation, Heterotopic | 1 | 2007 | 18 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10388 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 191 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2007 | 170 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 416 | 0.020 |
Why?
| | Spleen | 1 | 2007 | 514 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2691 | 0.010 |
Why?
| | Graft Survival | 1 | 2007 | 535 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1272 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 506 | 0.010 |
Why?
| | Graft Rejection | 1 | 2007 | 624 | 0.010 |
Why?
| | Myocardium | 1 | 2007 | 1002 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2015 | 10811 | 0.010 |
Why?
| | Adult | 1 | 2020 | 37929 | 0.010 |
Why?
| | Time Factors | 1 | 2007 | 6828 | 0.010 |
Why?
|
|
Kurche's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|